Krystal Biotech Toekomstige groei
Future criteriumcontroles 5/6
Krystal Biotech is forecast to grow earnings and revenue by 34.3% and 33.3% per annum respectively. EPS is expected to grow by 31.7% per annum. Return on equity is forecast to be 16.6% in 3 years.
Belangrijke informatie
34.3%
Groei van de winst
31.7%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | 33.3% |
| Toekomstig rendement op eigen vermogen | 16.6% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 21 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13
Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth
Jun 17Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 672 | 295 | 292 | 238 | 7 |
| 12/31/2025 | 477 | 166 | 184 | 186 | 9 |
| 12/31/2024 | 292 | 75 | 83 | 83 | 9 |
| 6/30/2024 | 166 | 106 | -23 | -17 | N/A |
| 3/31/2024 | 96 | 57 | -54 | -47 | N/A |
| 12/31/2023 | 51 | 11 | -101 | -89 | N/A |
| 9/30/2023 | 9 | -30 | -119 | -104 | N/A |
| 6/30/2023 | N/A | -140 | -130 | -102 | N/A |
| 3/31/2023 | N/A | -135 | -152 | -111 | N/A |
| 12/31/2022 | N/A | -140 | -154 | -101 | N/A |
| 9/30/2022 | N/A | -130 | -188 | -99 | N/A |
| 6/30/2022 | N/A | -115 | -182 | -87 | N/A |
| 3/31/2022 | N/A | -104 | -137 | -54 | N/A |
| 12/31/2021 | N/A | -70 | -116 | -48 | N/A |
| 9/30/2021 | N/A | -58 | -70 | -35 | N/A |
| 6/30/2021 | N/A | -52 | -52 | -35 | N/A |
| 3/31/2021 | N/A | -43 | -45 | -30 | N/A |
| 12/31/2020 | N/A | -32 | -41 | -26 | N/A |
| 9/30/2020 | N/A | -27 | -35 | -25 | N/A |
| 6/30/2020 | N/A | -22 | -29 | -23 | N/A |
| 3/31/2020 | N/A | -20 | -28 | -22 | N/A |
| 12/31/2019 | N/A | -19 | -25 | -19 | N/A |
| 9/30/2019 | N/A | -17 | -21 | -15 | N/A |
| 6/30/2019 | N/A | -16 | -18 | -13 | N/A |
| 3/31/2019 | N/A | -13 | -14 | -10 | N/A |
| 12/31/2018 | N/A | -11 | -12 | -9 | N/A |
| 9/30/2018 | N/A | -9 | -9 | -8 | N/A |
| 6/30/2018 | N/A | -11 | -7 | -7 | N/A |
| 3/31/2018 | N/A | -10 | N/A | -6 | N/A |
| 12/31/2017 | N/A | -8 | N/A | -4 | N/A |
| 9/30/2017 | N/A | -7 | N/A | -3 | N/A |
| 6/30/2017 | N/A | -2 | N/A | -2 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: KRYS's forecast earnings growth (34.3% per year) is above the savings rate (2.5%).
Winst versus markt: KRYS's earnings (34.3% per year) are forecast to grow faster than the US market (15.4% per year).
Hoge groeiwinsten: KRYS's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: KRYS's revenue (33.3% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: KRYS's revenue (33.3% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: KRYS's Return on Equity is forecast to be low in 3 years time (16.6%).